2024 ESMO｜14项LBA研究公布，消化系统肿瘤重磅进展标题速览！

前言

2024年欧洲肿瘤内科学会（ESMO）年会将于9月13日-17日在西班牙巴塞罗那召开。ESMO大会涵盖基础研究、转化研究以及最新临床研究进展，将为临床实践、多学科讨论等提供广阔、卓越的学术平台。

目前ESMO官网已在线公布了LBA研究的标题，医脉通小编第一时间整理了消化系统肿瘤领域的14项LBA重磅研究信息，带您一睹为快！

胃食管癌

[类型/摘要号] Proffered Paper LBA58

英文标题：A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG.

中文标题：围术期化疗联合或不联合术前放化疗应用于可切除胃癌的随机III期试验（AGITG-TOPGEAR）：AGITG、TROG、EORTC和CCTG组间试验的最终结果

讲者：Trevor Leong

[类型/摘要号] Proffered Paper LBA59

英文标题：Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial.

中文标题：改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗对比FLOT联合纳武利尤单抗治疗既往未经治疗的晚期或转移性胃或胃食管交界处腺癌患者——IKF AIO Moonlight试验的最终结果

讲者：Sylvie Lorenzen

[类型/摘要号] Mini Oral LBA60

英文标题：Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA).

中文标题：SHR-1701对比安慰剂联合化疗作为HER2阴性胃/胃食管交界处腺癌（G/GEJA）一线治疗的III期研究

讲者：彭智，北京大学肿瘤医院

肝细胞癌

[类型/摘要号] Presidential Symposium LBA3

英文标题：Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study.

中文标题：经动脉化疗栓塞 (TACE) 联合或不联合仑伐替尼 (len) + 帕博利珠单抗 (pembro) 治疗中晚期肝细胞癌 (HCC)：3期LEAP-012研究

讲者：Josep Llovet

[类型/摘要号] Proffered Paper LBA38

英文标题：Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308).

中文标题：Iparomlimab and tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗用于晚期肝细胞癌（aHCC）的一线治疗：一项随机、开放标签、II/III期研究（DUBHE-H-308）

讲者：秦叔逵，中国药科大学第一附属医院（南京天印山医院）

[类型/摘要号] Proffered Paper LBA39

英文标题：Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC).

中文标题：IMbrave050的最新疗效和安全性数据：阿替利珠单抗（atezo）+贝伐珠单抗（bev）辅助治疗对比主动监测应用于切除或消融后的高危肝细胞癌（HCC）患者的III期研究

讲者：Adam Yopp

[类型/摘要号] Proffered Paper LBA40

英文标题：Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC).

中文标题：III期ALTN-AK105-III-02研究的主要结果：安罗替尼联合派安普利单抗对比索拉非尼作为晚期肝细胞癌（aHCC）的一线治疗

讲者：周俭，复旦大学附属中山医院

胰腺癌

[类型/摘要号] Proffered Paper LBA62

英文标题：Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44.

中文标题：术前改良FOLFIRINOX（mFOLFIRINO）联合或不联合放化疗（CRT）应用于临界可切除胰腺癌：随机II期试验PANDAS/PRODIGE 44的结果

讲者：Aurélien Lambert

[类型/摘要号] Mini Oral LBA63

英文标题：A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy.

中文标题：伊立替康脂质体联合S-1对比伊立替康脂质体联合5-FU二线治疗吉西他滨化疗后转移性胰腺癌患者的随机I/II期研究

讲者：Anne M. Gehrels

结直肠癌

[类型/摘要号] Proffered Paper LBA24

英文标题：Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2.

中文标题：局部晚期dMMR结肠癌的新辅助免疫治疗：NICHE-2研究的3年DFS率

讲者：Myriam Chalabi

[类型/摘要号] Proffered Paper LBA25

英文标题：Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316).

中文标题：雷莫西尤单抗联合曲氟尿苷替匹嘧啶对比曲氟尿苷替匹嘧啶单药治疗既往接受治疗的转移性结直肠癌的随机III期试验：德国AIO（AIO-KRK-0316）RAMTAS/IKF643试验

讲者：Stefan Kasper-Virchow

[类型/摘要号] Proffered Paper LBA26

英文标题：SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC).

中文标题：SOLARIS（Alliance A021703）：维生素D（VitD）联合标准化疗和贝伐珠单抗（bev）治疗既往未经治疗的转移性结直肠癌患者的多中心双盲III期随机临床试验

讲者：Kimmie Ng

胃肠间质瘤

[类型/摘要号] Proffered Paper LBA79

英文标题：LENVAGIST - A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib.

中文标题：LENVAGIST - 一项多中心、比较性、安慰剂（P）对照、双盲、II 期研究，旨在探讨仑伐替尼（L）应用于伊马替尼和舒尼替尼治疗失败的晚期 GIST 患者中的疗效

讲者：Axel Le Cesne

肛门癌

[类型/摘要号] Presidential Symposium LBA2

英文标题：POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy (Chemo).

中文标题：POD1UM-303/InterAACT 2：Retifanlimab联合卡铂-紫杉醇（C-P）治疗既往未接受过全身化疗的无法手术的局部复发性或转移性肛管鳞状细胞癌（SCAC）患者的III期研究

讲者：Sheela Rao

备注：排名不分先后，顺序依据摘要号。

如有遗漏或任何问题，请给我们留言。

更多ESMO消化系统肿瘤精彩内容，

撰写：Babel

排版：Babel

执行：Squid

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。